Serum eosinophil cationic protein (ECP) levels were measured in 95 children with asthma to assess its role in monitoring inflammation and managing inhaled corticosteroid (ICS) therapy.
Significant differences in ECP levels were found between symptomatic and stable patients, indicating a higher presence of eosinophilic inflammation in those experiencing symptoms.
While ECP levels correlated with clinical evaluation, they did not effectively predict the necessity of continuing ICS therapy after withdrawal.